Apixaban
What is it: An oral Factor Xa inhibitor used off-label for microthrombi controlAKA: Eliquis- ⬤ Minimal research: Very little scientific study exists, with no or very few peer-reviewed studies. Insufficient data for conclusions.
- ⬤⬤ Limited research: Few studies exist, mostly small trials or case reports. Findings are preliminary and lack strong validation.
- ⬤⬤⬤ Moderately researched: Multiple studies, including mid-sized trials, exist. Some findings are replicated, but more research is needed.
- ⬤⬤⬤⬤ Well-researched: Supported by substantial evidence, including at least one large trial or meta-analysis.
- ⬤⬤⬤⬤⬤ Extensively studied: Numerous large studies and meta-analyses exist. Findings are widely accepted with strong scientific consensus.
- ⬤ Extremely Difficult to Access: Rare, experimental, or highly specialized. Requires multiple referrals, long wait times, travel, and strict follow-up.
- ⬤⬤ Difficult to Access: Limited to select centers with moderate barriers. Requires referral, potential travel, and wait times of weeks to months.
- ⬤⬤⬤ Moderately Accessible: Available in larger hospitals or clinics. Requires a basic referral, with moderate wait times and some coordination.
- ⬤⬤⬤⬤ Easy to Access: Widely available in most clinics. Minimal referral, short wait times, and simple preparation or follow-up.
- ⬤⬤⬤⬤⬤ Trivial to Access: Easily found in pharmacies or clinics. No referral needed, minimal wait, and straightforward access.
- ⬤ Up to $100
- ⬤⬤ Up to $500
- ⬤⬤⬤ Up to $2000
- ⬤⬤⬤⬤ Up to $10,000
- ⬤⬤⬤⬤⬤ More than $10,000
To calculate the reported effectiveness for a patient view, the model first analyses whether it can be ascertained that the person writing the review has had direct experience of the treatment for themselves or a loved one. If so, it then uses sentiment analysis to rate their view from 1-5 on how effective this treatment was for them, with 1 being the least effective, and 5 the most effective.
3 Resources
Referenced in this guide
3 Expert views
Contributed in this guide
5 Patient views
Contributed in this guide
Figure out what Apixaban means for you
Page contents
Basics: What you need to know
Apixaban (Eliquis) is a direct Factor Xa inhibitor co-developed by Bristol-Myers Squibb and Pfizer. Formally approved for preventing stroke in non-valvular atrial fibrillation and treating deep vein thrombosis or pulmonary embolism, it has recently attracted attention for off-label use in individuals with Long Covid. Potential microthrombotic complications in Long Covid have led some clinicians to investigate Apixaban’s ability to reduce these clots, though evidence remains incomplete. Below is a detailed overview:
History and development
- Developed collaboratively by Bristol-Myers Squibb and Pfizer, Apixaban emerged out of research aiming to create a novel orally administered factor Xa inhibitor for reducing clot formation.
- FDA approval granted in 2012 for stroke prevention in non-valvular atrial fibrillation, and subsequent approvals followed for deep vein thrombosis and pulmonary embolism treatment.
- Continued exploration of its anticoagulant properties has led to off-label interest for diverse conditions, including suspected microthrombotic events in Long Covid.
- Refinement of dosage and monitoring techniques has steadily advanced, though use in off-label contexts often requires additional oversight.
What is known
- Direct factor Xa blockade prevents the conversion of prothrombin to thrombin, reducing clot formation in blood vessels.
- Proven benefit in stroke risk reduction for specific cardiovascular conditions, supported by multiple large-scale studies.
- Potential microthrombotic impact is the rationale behind its off-label adoption in Long Covid, aiming to lower small-scale clot formation that might worsen symptoms.
- Possible secondary perks include reduced systemic inflammation and improved circulation in patients with coagulation imbalances, though these benefits remain less firmly established.
- Use requires caution due to bleeding risks, especially in vulnerable populations or those on additional antithrombotic therapies.
What is not known
- Long-term efficacy in Long Covid remains unclear, with limited clinical data supporting off-label usage.
- Optimal dosage strategies for post-viral syndromes like Long Covid are not well defined, leading to potential under- or over-medication.
- Exact mechanism by which factor Xa inhibition might reduce or prevent microclots in Long Covid has not been conclusively mapped out.
- Potential triggers of increased bleeding or bruising may overshadow possible benefits in certain patients, indicating the need for vigilant monitoring.
- Future research is required to clarify the balance between risk and benefit, ensuring that microthrombotic theories and off-label use are well-substantiated.
- Directly inhibits Factor Xa to block thrombin generation and minimize clot formation.
- Reduces coagulation by lowering the production of fibrin, a key factor in clot stability.
- Targets microthrombi possibly lingering in small vessels, helping to alleviate vascular strain.
- Oral dosage form simplifies administration and monitoring compared to certain injectable anticoagulants.
- Bleeding risk such as bruising or prolonged bleeding.
- Gastrointestinal discomfort including nausea or indigestion.
- Potential for anemia if chronic blood loss occurs.
- Drug interactions with certain medications that also affect blood coagulation.
- Liver enzyme elevations in rare instances, requiring periodic monitoring.
- Uncertain benefit in microthrombotic processes of Long Covid due to limited research.
- Off-label usage sparks debate among clinicians because robust safety and efficacy data are lacking.
- Risk-balancing concerns arise from potential bleeding episodes weighed against possible symptom relief.
- Emerging data may shape future consensus, but current studies remain inconclusive.
Patient views
Experiences
- Patients appreciate Apixaban's role in improving mobility and reducing brain fog.
- Some report significant symptom relief when combined with other treatments.
- It is seen as effective for addressing microclots in Long Covid.
- Patients value its convenience compared to older anticoagulants.
Challenges
- Risk of bleeding is a major concern for patients.
- Some experience worsening symptoms initially due to inflammatory responses.
- Relapses after initial improvement are reported by some patients.
- It may not work for all Long Covid phenotypes.
Tips
- Consult an experienced doctor before starting Apixaban.
- Be prepared for initial worsening of symptoms.
- Consider using a proton pump inhibitor to protect the stomach.
- Monitor progress and adjust treatment as needed.
To calculate the reported effectiveness for a patient view, the model first analyses whether it can be ascertained that the person writing the review has had direct experience of the treatment for themselves or a loved one. If so, it then uses sentiment analysis to rate their view from 1-5 on how effective this treatment was for them, with 1 being the least effective, and 5 the most effective.
Patient view
Clopidogrel and apixaban. I was recommended aspirin too but can’t tolerate it. Please note these drugs come with significant risk so need to be prescribed by an experienced doctor. Do see the review of my experience on my profile if you’re interested.
March 2025 • Turnto Comment
Patient view
I had HELP apheresis, hyperbaric oxygen and blood thinners to address microclots. Probably all helped to some extent but I think probably the blood thinners most, given that I got a significant step-wise improvement with each titration up in dose.
The patient took clopidogrel and apixaban (was recommended aspirin too to make it ‘triple therapy’ but can’t tolerate aspirin). Obviously these meds aren’t without risk and need an experienced doctor to prescribe.
Over a few months, these meds got the patient from mainly sofa bound to walking 3 km a day, and improved severe brain fog to more of a moderate cognitive fatigue. Unfortunately after a few months the patient relapsed and we now think that there’s something very inflammatory and /or autoimmune going on - but other people have maintained their progress from blood thinners, especially if they’re treated earlier in illness.
‘Triple Therapy’ and ‘Professor Resia Pretorius’ are good search terms if you want to google more about the science! 😊
December 2024 • Turnto Comment
Expert views
What they liked
- Experts appreciate Apixaban's role in reducing microclots.
- Positive outcomes include improved blood flow and reduced symptoms.
- Apixaban is part of effective triple therapy protocols.
- Experts value its ability to target hyperactive platelets.
What they didn't like
- Risk of serious bleeding, including brain and intestinal bleeds.
- Concerns about safety in high-risk patients.
- Some experts find triple therapy overly aggressive.
- Limited data on long-term effects of Apixaban.
What are they unsure about
- Experts question its effectiveness for all Long Covid patients.
- Uncertainty about long-term safety and outcomes.
- Lack of clarity on optimal dosage and duration.
- Experts unsure about its role in autoimmune-related symptoms.
3 expert views
Expert view
Dr. Asad Khan discusses the use of anticoagulants, including Apixaban, in treating Long Covid. He highlights that removing clots and stabilizing the endothelium (the inner lining of blood vessels) can prevent recurrence of symptoms. He mentions that antibodies triggered by the spike protein may attack various parts of the body, and targeting these rogue antibodies might be necessary for some patients. Dr. Khan emphasizes the effectiveness of combining anticoagulants with apheresis, a blood filtration process, noting that this combination has reduced the number of treatment cycles needed. He also describes the three-drug regimen used, which includes aspirin, clopidogrel, and an anticoagulant like Apixaban, to address different aspects of clotting.
December 2021 • Episode 21: Dr Asad Khan - H.E.L.P. Apheresis
Expert view
Professor Jack Lambert, an infectious disease expert, discusses the use of anticoagulants like Apixaban for treating Long Covid. He acknowledges that while studies in the U.S. have shown some benefits, the risks are significant, including life-threatening complications like brain bleeds and intestinal bleeds. Lambert suggests safer alternatives, such as baby aspirin or natural supplements like natto kinase, which have anticoagulant effects and may work on the spike protein. He emphasizes the importance of avoiding risky treatments and focusing on safe options to improve patients' quality of life.
March 2023 • Episode 53: Prof. Jack Lambert - LDN protocol
What and who it targets
Clotting risk patients
High risk of blood clots or thrombosis.
Severe inflammation cases
Inflammation exacerbating Long Covid symptoms.
Post-hospitalization patients
Recovering from severe Covid-19 cases.
Cardiovascular complications
Heart-related issues linked to Long Covid.
Accessibility
- ⬤ Extremely Difficult to Access: Rare, experimental, or highly specialized. Requires multiple referrals, long wait times, travel, and strict follow-up.
- ⬤⬤ Difficult to Access: Limited to select centers with moderate barriers. Requires referral, potential travel, and wait times of weeks to months.
- ⬤⬤⬤ Moderately Accessible: Available in larger hospitals or clinics. Requires a basic referral, with moderate wait times and some coordination.
- ⬤⬤⬤⬤ Easy to Access: Widely available in most clinics. Minimal referral, short wait times, and simple preparation or follow-up.
- ⬤⬤⬤⬤⬤ Trivial to Access: Easily found in pharmacies or clinics. No referral needed, minimal wait, and straightforward access.
- ⬤ Up to $100
- ⬤⬤ Up to $500
- ⬤⬤⬤ Up to $2000
- ⬤⬤⬤⬤ Up to $10,000
- ⬤⬤⬤⬤⬤ More than $10,000
Method to access
- Requires a prescription from a healthcare provider.
- Available at most pharmacies.
- May require prior authorization from insurance for coverage.
- Not typically prescribed specifically for Long Covid.
Cost
- In the U.S., the cost for a 30-day supply of Apixaban (Eliquis) ranges from $231 to $591.
- Generic versions may be less expensive.
- Costs vary by region and pharmacy, with mail-order options potentially reducing expenses.
Insurance cover
- Commonly covered by health insurance for approved indications like atrial fibrillation or deep vein thrombosis.
- Coverage for Long Covid treatment may be inconsistent due to lack of standardized guidelines.
- Patients may need to appeal denied claims.
Locations
- Cleveland Clinic: Offers Long Covid recovery services, including anticoagulant treatments.
- Penn Medicine: Post-COVID Assessment and Recovery Clinic provides care for lingering symptoms.
- Yale Medicine: Specializes in Long Covid care and research.
- Long Covid Alliance: Directory of clinics specializing in Long Covid care.
Frequently asked questions
Key resources
Explore other treatments
It's a lot of information, isn't it?
Turnto's personal AI Assistant can help you figure out what this all means for you
© 2026 Turnto
